Allergan lifts earnings target, says no drug price hikes this year

By Manas Mishra (Reuters) - Drugmaker Allergan Plc raised its yearly earnings forecast on Thursday thanks to rising sales of mainstay product Botox, and said it did not expect to increase drug prices this year. The remarks about curbing price hikes echoed sentiment from Allergan's peers including Pfizer, Merck and Novartis, as U.S. President Donald Trump's administration intensifies efforts to tackle escalating healthcare costs.

Reuters July 27, 2018 00:05:10 IST
Allergan lifts earnings target, says no drug price hikes this year

Allergan lifts earnings target says no drug price hikes this year

By Manas Mishra

(Reuters) - Drugmaker Allergan Plc raised its yearly earnings forecast on Thursday thanks to rising sales of mainstay product Botox, and said it did not expect to increase drug prices this year.

The remarks about curbing price hikes echoed sentiment from Allergan's peers including Pfizer, Merck and Novartis, as U.S. President Donald Trump's administration intensifies efforts to tackle escalating healthcare costs.

Allergan Chief Executive Officer Brent Saunders highlighted his company's "social contract with patients," and its pledge in 2016 to limit yearly price increases to 10 percent.

"My opinion is the days of driving growth through large price increases are coming to an end in our industry," Saunders told analysts on a conference call, adding that the company had already hiked prices at the start of the year.

The Dublin, Ireland-incorporated company lifted its earnings target to reflect strength in its medical aesthetics business, which houses blockbuster wrinkle treatment Botox and the CoolSculpting system that helps people slim down by freezing fat away.

Sales of Botox, as well as sales from Allergan's second most important drug, Restasis, exceeded Wall Street expectations by a comfortable margin in the second quarter ended June 30.

Overall revenue rose 2.9 percent to $4.12 billion.

ON THE DEFENSIVE

Saunders also defended Allergan's leadership structure, under which he is both CEO and chairman.

Investors have called for changes at the top at Allergan, following a series of setbacks to its pipeline of potential new drugs and a string of acquisitions that have taken the company's debt pile past $25 billion.

Two prominent shareholders, Appaloosa Management and Senator Investment Group, asked the drugmaker's board last month to split the roles of CEO and chairman and also review its acquisition strategy.

However, the board wants Saunders to keep his dual role alongside the lead independent director who also has significant responsibilities, Saunders said. This structure provided "the right independence, oversight and leadership for our board," he said.

Allergan's shares have fallen 30 percent in the past 12 months. The stock was slightly higher at $177.07 on Thursday afternoon.

The company reported a smaller net loss attributable to ordinary shareholders of $472.5 million, or $1.39 per share in the second quarter.

Excluding one-time items, the drugmaker earned $4.42 per share, topping analysts' average estimate of $4.13, according to Thomson Reuters I/B/E/S.

Allergan now expects 2018 earnings of between $16 and $16.50 per share, higher than an earlier estimate of between $15.65 and $16.25.

(Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty, Sriraj Kalluvila and Sai Sachin Ravikumar)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

France, Germany to agree to NATO role against Islamic State - sources
| Reuters
World

France, Germany to agree to NATO role against Islamic State - sources | Reuters

By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States

China's Xi says navy should become world class
| Reuters
World

China's Xi says navy should become world class | Reuters

BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.